Adverse events (grade ≥ 3) · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy showed no clear difference in adverse events (CTCAE grade ≥ 3) (longest available compared with standard therapy (moderate certainty).
1 finding from 1 review
Adverse events: infections (CTCAE grade ≥ 3) (longest available · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher adverse events: infections (CTCAE grade ≥ 3) (longest available compared with standard therapy (moderate certainty).
1 finding from 1 review
Intervention not reported
Overall survival (at 36 months) · patients after allogeneic stem cell or bone marrow transplantation
The intervention showed no clear difference in overall survival (at 36 months) (moderate certainty).
1 finding from 1 review
Intervention not reported
Acute GVHD II to IV (90 days) · patients after allogeneic stem cell or bone marrow transplantation
The intervention leads to lower acute GVHD II to IV (90 days) (high certainty).
1 finding from 1 review
Intervention not reported
Overall Chronic GVHD (up to 36 months) · patients after allogeneic stem cell or bone marrow transplantation
The intervention leads to lower overall Chronic GVHD (up to 36 months) (high certainty).
1 finding from 1 review
Intervention not reported
Incidence of relapse (up to 36 months) · patients after allogeneic stem cell or bone marrow transplantation
The intervention showed no clear difference in incidence of relapse (up to 36 months) (moderate certainty).
1 finding from 1 review
Intervention not reported
Non‐relapse mortality (at 36 months) · patients after allogeneic stem cell or bone marrow transplantation
The intervention showed no clear difference in non‐relapse mortality (at 36 months) (moderate certainty).
1 finding from 1 review
Intervention not reported
Graft failure (during study) · patients after allogeneic stem cell or bone marrow transplantation
The intervention showed no clear difference in graft failure (during study) (low certainty).
1 finding from 1 review
Intervention not reported
Adverse Events (during study) · patients after allogeneic stem cell or bone marrow transplantation
1 finding from 1 review
All‐cause mortality at up to day 28 ‐ total · individuals with moderate to severe disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in all‐cause mortality at up to day 28 ‐ total compared with placebo or standard care alone (high certainty).
1 finding from 1 review
Quality of life, · individuals with moderate to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events · individuals with moderate to severe disease
1 finding from 1 review
Serious adverse events · individuals with moderate to severe disease
It is very uncertain whether summary of findings table ‐ Convalescent plasma changes serious adverse events compared with standard plasma (very low certainty).
1 finding from 1 review
All‐cause mortality at up to day 28 · individuals with moderate to severe disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in all‐cause mortality at up to day 28 compared with human immunoglobulin (low certainty).
1 finding from 1 review
Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · individuals with moderate to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement: participants discharged from hospital ‐ not reported · individuals with moderate to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not reported · individuals with moderate to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events ‐ not reported · individuals with moderate to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ not reported · individuals with moderate to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at up to day 28 · outpatients withmild disease
It is very uncertain whether summary of findings table ‐ Convalescent plasma changes all‐cause mortality at up to day 28 compared with placebo or standard care alone (very low certainty).
1 finding from 1 review